IL132398A - History of piparazine and pharmaceutical preparations containing them - Google Patents

History of piparazine and pharmaceutical preparations containing them

Info

Publication number
IL132398A
IL132398A IL13239898A IL13239898A IL132398A IL 132398 A IL132398 A IL 132398A IL 13239898 A IL13239898 A IL 13239898A IL 13239898 A IL13239898 A IL 13239898A IL 132398 A IL132398 A IL 132398A
Authority
IL
Israel
Prior art keywords
alkyl
methyl
naphthyl
optionally substituted
substituted phenyl
Prior art date
Application number
IL13239898A
Other languages
English (en)
Hebrew (he)
Other versions
IL132398A0 (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL132398A0 publication Critical patent/IL132398A0/xx
Publication of IL132398A publication Critical patent/IL132398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13239898A 1997-06-12 1998-06-11 History of piparazine and pharmaceutical preparations containing them IL132398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87359997A 1997-06-12 1997-06-12
US09/094,397 US6207665B1 (en) 1997-06-12 1998-06-09 Piperazine derivatives and their use as anti-inflammatory agents
PCT/EP1998/003503 WO1998056771A2 (en) 1997-06-12 1998-06-11 Piperazine derivatives and their use as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
IL132398A0 IL132398A0 (en) 2001-03-19
IL132398A true IL132398A (en) 2004-08-31

Family

ID=26788818

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13239898A IL132398A (en) 1997-06-12 1998-06-11 History of piparazine and pharmaceutical preparations containing them

Country Status (22)

Country Link
US (8) US6207665B1 (de)
EP (2) EP1254899B1 (de)
JP (1) JP2002503239A (de)
KR (1) KR100549137B1 (de)
AT (2) ATE296292T1 (de)
AU (1) AU735462B2 (de)
CA (1) CA2293382C (de)
CZ (1) CZ295784B6 (de)
DE (2) DE69811363T2 (de)
DK (2) DK1254899T3 (de)
EA (2) EA004038B1 (de)
EE (4) EE04056B1 (de)
ES (2) ES2191320T3 (de)
HU (1) HUP0003929A3 (de)
IL (1) IL132398A (de)
IS (1) IS2241B (de)
NO (2) NO317343B1 (de)
PL (1) PL337758A1 (de)
PT (1) PT1254899E (de)
SK (2) SK285162B6 (de)
TR (1) TR199903034T2 (de)
WO (1) WO1998056771A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
CA2361256A1 (en) * 1999-01-29 2000-08-03 James B. Rottman Method of treating demyelinating inflammatory disease using ccr1 antagonists
SK13652002A3 (sk) * 2000-03-31 2004-01-08 Pfizer Products Inc. Deriváty piperazínu
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
LT5132B (lt) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
US20020173524A1 (en) * 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
HUP0301442A3 (en) * 2000-10-19 2007-03-28 Pfizer Prod Inc Bridged piperazine derivatives and pharmaceutical compositions containing them
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
WO2002094264A1 (en) * 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DE60209348T2 (de) * 2001-06-20 2006-10-12 Merck & Co., Inc. Dipeptidylpeptidase-hemmer zur behandlung von diabetes
EE200400023A (et) * 2001-06-20 2004-06-15 Pfizer Products Inc. Uued sulfoonhappe derivaadid
US6812230B2 (en) * 2001-08-07 2004-11-02 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists for the treatment of progressive renal fibrosis
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
US20030087913A1 (en) * 2001-10-18 2003-05-08 Schering Ag Solid pharmaceutical agent formulation for a piperazine urea derivative
CZ2004519A3 (cs) * 2001-10-22 2004-12-15 Pfizer Products Inc. Deriváty piperazinu s účinky antagonisty receptoru CCR1
KR100472086B1 (ko) * 2001-11-23 2005-02-21 한국화학연구원 항산화 활성을 갖는 3,5-디알콕시-4-히드록시페닐기로치환된 피페라진 유도체, 그의 제조방법 및 이를 포함하는약학적 조성물
GB0203299D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207447D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) * 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
US20040092529A1 (en) * 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
CA2507657C (en) 2002-12-11 2011-05-31 Bayer Schering Pharma Aktiengesellschaft 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
JP2006509815A (ja) * 2002-12-13 2006-03-23 ファイザー・プロダクツ・インク 新規なリン含有誘導体
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
WO2005102340A1 (en) * 2003-05-30 2005-11-03 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
CA2534941A1 (en) * 2003-08-22 2005-03-03 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
US7825147B2 (en) 2003-08-29 2010-11-02 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2007505837A (ja) 2003-09-15 2007-03-15 オードウェイ リサーチ インスティテュート 甲状腺ホルモンアナログおよび新脈管形成における使用の方法
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
CA2554974A1 (en) * 2004-02-06 2005-08-25 Schering Aktiengesellschaft Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
EA200601514A1 (ru) * 2004-02-24 2007-02-27 Шеринг Акциенгезельшафт Производные пиперазинмочевины для лечения эндометриоза
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
SE0400441D0 (sv) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
CN1950082B (zh) * 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
ES2251292B1 (es) * 2004-04-20 2007-07-01 Inke, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis.
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
AU2005284879B2 (en) 2004-09-15 2011-04-14 Albany College Of Pharmacy And Health Sciences Thyroid hormone analogs for promoting angiogenesis
EP1749519A1 (de) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
DE602006011363D1 (de) * 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
AU2007254179B2 (en) * 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
JP2010513526A (ja) 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2008090357A2 (en) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. N, n; -substituted piperazines binding to melanocortin receptor
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
ES2703176T3 (es) 2010-03-11 2019-03-07 Univ New York Compuestos amido como moduladores de RORgammat y usos de los mismos
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
KR101380466B1 (ko) * 2011-09-27 2014-04-02 한국생명공학연구원 ＨＩＦ―１α 활성을 저해하는 신규 화합물 및 그 제조방법
CN102408395B (zh) * 2011-10-24 2014-04-02 广西师范大学 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
EP2771484A1 (de) 2011-10-28 2014-09-03 Galderma Research & Development Neue leukozyteninfiltratmarker für rosacea und verwendungen davon
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
CN103724296B (zh) * 2013-12-12 2015-09-02 南京医科大学 芳基取代的哌嗪羰基衍生物及其制备方法和应用
US10676711B2 (en) 2014-06-06 2020-06-09 Riken Agent for inducing callus and method for inducing callus
CN105218501A (zh) * 2014-07-03 2016-01-06 南京大学 含哌嗪环的香豆素类衍生物及其制备与在抗菌药物中的应用
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016056581A1 (ja) 2014-10-08 2016-04-14 国立研究開発法人理化学研究所 植物成長促進剤及び植物成長促進方法
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
WO2017127306A1 (en) 2016-01-18 2017-07-27 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
CN110372638B (zh) * 2018-04-13 2023-09-22 中国药科大学 哌嗪类ampk激动剂及其医药用途
CN108484558A (zh) * 2018-05-14 2018-09-04 中国药科大学 黄酮类ampk激动剂及其医药用途
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
CA3220332A1 (en) * 2021-06-07 2022-12-15 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
EP4115885A1 (de) 2021-07-05 2023-01-11 Charité - Universitätsmedizin Berlin Pharmazeutische zusammensetzung mit bay 86-5277 und salzen davon zur verwendung bei der behandlung von virusinfektionen und hyperentzündungen
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
EP4531845A4 (de) * 2022-06-03 2026-04-29 Imbria Pharmaceuticals Inc Verbindungen und verfahren zur erhöhung der effizienz des herzstoffwechsels
CN116803981A (zh) * 2023-06-28 2023-09-26 温州医科大学 一种含哌嗪的酰胺类或磺酰胺类抗炎化合物及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324117A (en) 1967-06-06 Carboxylic acid piperazides and process for their manufacture
FR7524M (de) 1968-03-12 1969-12-15
DE2304155A1 (de) * 1973-01-29 1974-08-01 Ichthyol Ges Cordes Hermanni & N-acylierte substituierte piperazinbzw. homopiperazinderivate, sowie verfahren zu ihrer herstellung
DE2730174C2 (de) 1977-07-04 1981-12-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Aminobenzoesäurederivate und Arzneimittel enthaltend solche Aminobenzoesäurederivate
DE3060330D1 (en) * 1979-04-06 1982-06-09 Bayer Ag Azolyloxy-acetamides, process for their preparation and their use as herbicides
IT1151533B (it) 1982-03-29 1986-12-24 Ravizza Spa Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina
IT1151532B (it) 1982-03-29 1986-12-24 Ravizza Spa Procedimento per la preparazione di p. clorofenossiacetil-piperonilpiperazina
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
CA1277663C (en) 1985-02-04 1990-12-11 Richard A. Mueller Heterocyclic amides
DE3614363A1 (de) 1986-04-28 1987-10-29 Hoechst Ag Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
JPS6314774A (ja) 1986-07-07 1988-01-21 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
FR2611713B1 (fr) 1987-02-27 1990-11-30 Adir Nouveaux derives de l'acide (dihydro-2,3 oxo-2 benzofurannyl-3)-2 acetique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US4873253A (en) 1987-03-30 1989-10-10 Shosuke Okamoto Phenylalanine derivative and proteinase inhibitor
CS260089B1 (cs) 1987-05-12 1988-11-15 Miroslav Protiva Piperazidy methoxyfenoxyoctových kyselin a jejich hydrochloridy
AT389112B (de) 1987-10-08 1989-10-25 Hoechst Ag Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
FR2623808B1 (fr) 1987-12-01 1990-03-09 Adir Nouveaux derives flavonoides (benzyl-4 piperazinyl-1)-2 oxo-2 ethylene substitues, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5232923A (en) * 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
NZ228329A (en) 1988-03-18 1991-12-23 Mitsui Toatsu Chemicals Catechol derivatives and pharmaceutical compositions thereof
US5010080A (en) 1988-12-02 1991-04-23 G. D. Searle & Co. Use of heterocyclic amides to inhibit tumor metastasis
US5089506A (en) * 1990-04-30 1992-02-18 G. D. Searle & Co. Ethanobicyclic amine derivatives for cns disorders
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
FR2689127B1 (fr) * 1992-03-31 1994-05-06 Adir Cie Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5272175A (en) 1992-05-20 1993-12-21 G. D. Searle & Co. Substituted tyrosyl diamide compounds
US5389645A (en) 1992-08-13 1995-02-14 G. D. Searle & Co. Substituted tyrosyl diamine amide compounds
DE59309867D1 (de) 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
IL110040A (en) 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
AU674613B2 (en) 1993-09-28 1997-01-02 Otsuka Pharmaceutical Co., Ltd. Quinoxaline derivative as antidiabetic agent
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
FR2724656B1 (fr) 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1996034864A1 (en) 1995-05-02 1996-11-07 Schering Corporation Piperazino derivatives as neurokinin antagonists
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998004554A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
CN1248968A (zh) 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IL145757A (en) 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
US6521619B2 (en) 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)

Also Published As

Publication number Publication date
AU735462B2 (en) 2001-07-12
US20030139425A1 (en) 2003-07-24
US20060135487A1 (en) 2006-06-22
EE200200684A (et) 2003-04-15
SK285162B6 (sk) 2006-07-07
NO20031373D0 (no) 2003-03-26
HUP0003929A3 (en) 2001-08-28
IS5258A (is) 1999-11-19
IS2241B (is) 2007-05-15
US7268140B2 (en) 2007-09-11
US6534509B1 (en) 2003-03-18
EP1254899A3 (de) 2003-02-19
DK0988292T3 (da) 2003-04-22
ATE296292T1 (de) 2005-06-15
CZ295784B6 (cs) 2005-11-16
AU8625898A (en) 1998-12-30
KR100549137B1 (ko) 2006-02-03
ES2242824T3 (es) 2005-11-16
CA2293382C (en) 2008-03-11
SK285445B6 (sk) 2007-01-04
US6541476B1 (en) 2003-04-01
KR20010013703A (ko) 2001-02-26
US6977258B2 (en) 2005-12-20
EE9900565A (et) 2000-06-15
EE200200682A (et) 2003-04-15
SK171399A3 (en) 2000-09-12
US20030158205A1 (en) 2003-08-21
DE69811363D1 (de) 2003-03-20
IL132398A0 (en) 2001-03-19
EA199901063A1 (ru) 2001-04-23
DE69830341T2 (de) 2006-02-02
HUP0003929A2 (hu) 2001-05-28
EA004038B1 (ru) 2003-12-25
EE200200683A (et) 2003-04-15
NO996068L (no) 2000-02-11
JP2002503239A (ja) 2002-01-29
EP1254899B1 (de) 2005-05-25
CA2293382A1 (en) 1998-12-17
EE04056B1 (et) 2003-06-16
US20020177598A1 (en) 2002-11-28
ATE232522T1 (de) 2003-02-15
NO996068D0 (no) 1999-12-09
WO1998056771A3 (en) 1999-03-11
CZ448199A3 (cs) 2000-04-12
DK1254899T3 (da) 2005-09-05
EA200200262A1 (ru) 2002-06-27
EP0988292B1 (de) 2003-02-12
ES2191320T3 (es) 2003-09-01
PT1254899E (pt) 2005-10-31
US6573266B1 (en) 2003-06-03
EP1254899A2 (de) 2002-11-06
PL337758A1 (en) 2000-09-11
NO20031373L (no) 2000-02-11
DE69830341D1 (de) 2005-06-30
NO317343B1 (no) 2004-10-11
EP0988292A2 (de) 2000-03-29
WO1998056771A2 (en) 1998-12-17
US6555537B2 (en) 2003-04-29
DE69811363T2 (de) 2003-11-27
TR199903034T2 (xx) 2000-06-21
US6972290B2 (en) 2005-12-06
US6207665B1 (en) 2001-03-27

Similar Documents

Publication Publication Date Title
US6555537B2 (en) Piperazine derivatives and their use as anti-inflammatory agents
CN1867336B (zh) 1-芳基-4-取代的哌嗪衍生物及其制药用途
JP2007502287A (ja) メラニン凝集ホルモン受容体アンタゴニスト
US20100240618A1 (en) Substituted piperazines
US20080119471A1 (en) Piperazine urea derivatives for the treatment of endometriosis
MXPA99011506A (en) Piperazine derivatives and their use as anti-inflammatory agents
CN1938029A (zh) 具有趋化因子抑制作用的哌嗪衍生物及其在治疗多发性骨髓瘤中的应用
MXPA06009687A (en) Piperazine urea derivatives for the treatment of endometriosis
AU2004266153A1 (en) Chemokine inhibiting piperazine derivatives and their use to treat myocarditis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees